LONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning and Wednesday afternoon:
----------
FTSE 100
----------
NOMURA CUTS BG GROUP TO 'NEUTRAL' ('BUY') - PRICE TARGET 1350 PENCE
----------
TRADERS: INVESTEC CUTS RBS TO 'SELL' ('HOLD')
----------
GOLDMAN CUTS TESCO PRICE TARGET TO 250 (270) PENCE - 'SELL'
----------
GOLDMAN CUTS ITV PRICE TARGET TO 235 (240) PENCE - 'BUY'
----------
GOLDMAN CUTS BABCOCK PRICE TARGET TO 1,545 (1,620) PENCE - 'CONVICTION BUY'
----------
GOLDMAN CUTS PEARSON TO 'SELL' ('NEUTRAL') - TARGET 1,130 (1,080) PENCE
----------
TRADERS: MORGAN STANLEY CUTS ANGLO AMERICAN TO 'UNDERWEIGHT' ('EQUAL-WEIGHT')
----------
SOCGEN RAISES GLAXOSMITHKLINE PRICE TARGET TO 2075 (2050) PENCE - 'BUY'
----------
S&P CAPITAL IQ CUTS SAINSBURY TO 'HOLD' ('BUY') - TARGET 360 (370) PENCE
----------
FTSE 250
----------
NUMIS CUTS PZ CUSSONS PRICE TARGET TO 352 (364) PENCE - 'HOLD'
----------
LIBERUM CUTS OXFORD INSTRUMENTS PRICE TARGET TO 1600 (1625) PENCE - 'BUY'
----------
JPMORGAN INITIATES OCADO WITH 'OVERWEIGHT' - TARGET 500 PENCE
----------
CITIGROUP RAISES PROVIDENT FIN. TO 'BUY' ('NEUTRAL') - TARGET 2,530 (1,825) P.
----------
TRADERS: EXANE BNP CUTS OPHIR ENERGY TO 'NEUTRAL' ('OUTPERFORM')
----------
GOLDMAN CUTS LONMIN PRICE TARGET TO 270 (280) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS INFORMA PRICE TARGET TO 527 (543) PENCE - 'SELL'
----------
UBS RAISES COBHAM PRICE TARGET TO 315 (290) PENCE - 'NEUTRAL'
----------
MAIN MARKET AND AIM
----------
CANACCORD RAISES CARETECH PRICE TARGET TO 304 (275) PENCE - 'BUY'
----------
LIBERUM RAISES FLYBE GROUP PRICE TARGET TO 190 (175) PENCE - 'BUY'
----------
CITIGROUP CUTS CHEMRING GROUP PRICE TARGET TO 245 (260) PENCE - 'NEUTRAL'
----------
TRADERS: NUMIS INITIATES PLEXUS HLDGS WITH 'ADD' - TARGET 364 PENCE
----------
Copyright 2014 Alliance News Limited. All Rights Reserved.
Fate of most remaining Zantac lawsuits weighed by Delaware judge
Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.
Read more